Viridian Therapeutics price target lowered to $37 from $38 at JMP Securities

JMP Securities lowered the firm’s price target on Viridian Therapeutics to $37 from $38 and keeps an Outperform rating on the shares. Viridian reaffirmed progress with the late-stage development programs for thyroid eye disease including both intravenous and subcutaneous candidates, the analyst tells investors in a research note. The company’s quarterly results were below estimates due to higher-than-expected operating expenses as the company continues to invest in its late-stage TED programs and emerging pipeline, the firm says.